Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
Adoptively transferred tumor-draining lymph node–derived T cells recognize the neoantigen peptide–HLA class I complex via their native TCRs and directly kill target cells through CTL effector mechanisms (perforin/granzyme release and Fas–FasL apoptosis), aided by cytotoxic cytokines.
Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
Adoptively transferred tumor-draining lymph node–derived T cells recognize the shared tumor antigen peptide on HLA class I via native TCRs and directly kill targets via perforin/granzyme release and Fas–FasL apoptosis, with supportive cytokine effects (e.g., IFN-γ, TNF).
Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
Adoptively transferred tumor-primed T cells recognize the neoantigen–HLA class II complex via their native TCR and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis, with cytokines (e.g., IFN-γ, TNF) augmenting cytotoxicity.
Autologous, expanded tumor-draining lymph node–derived T cells administered as adoptive cell therapy.
Autologous T cells harvested from tumor-draining lymph nodes are expanded ex vivo and reinfused. These lymphocytes are enriched for tumor-primed, antigen-specific T cells that recognize tumor antigens via their native TCRs, then mediate cytotoxic killing and cytokine-driven immune responses against tumor cells.
Infused tumor-primed LNL T cells recognize the tumor-associated peptide presented on HLA class II via their native TCRs and directly lyse target cells through perforin/granzyme and/or Fas–FasL pathways, with cytokines (e.g., IFN-γ, TNF) aiding cytotoxicity.
Investigational allogeneic CD19-directed CAR NK cell therapy (adoptive cell immunotherapy) engineered to recognize CD19 and trigger NK cell cytotoxicity to deplete CD19+ B cells.
Off‑the‑shelf allogeneic natural killer cells engineered with a CD19‑specific chimeric antigen receptor containing OX40 and CD3ζ signaling domains and membrane‑bound IL‑15 to enhance survival/persistence. Upon binding CD19 on B cells, the CAR NK cells degranulate (perforin/granzyme) and secrete pro‑inflammatory cytokines, leading to targeted lysis and depletion of CD19+ B cells.
CD19-directed CAR NK cells bind CD19+ cells and kill via NK cell degranulation (perforin/granzyme) leading to lytic/apoptotic death.